Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 22Thoracic 21Gastrointestinal 9Breast 4Lymphoid 2Genitourinary 2CNS 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Ovarian Neoplasms 7Carcinoma, Ovarian Epithelial 7Fallopian Tube Neoplasms 6Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Brenner Tumor 2Urinary Bladder Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Erlotinib Hydrochloride × Gynecologic × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡